12 August 2021 in Nature Medicine
8 May 2019 in Cardiovascular Drugs and Therapy
Background The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failure and preserved ejection fraction (HFpEF) and myocardial fibrosis. HFpEF is a diverse syndrome associated with substantial morbidity and mortality. Myocardial fibrosis is a key pathophysiological mechanism of HFpEF and myocardial fibrotic burden is strongly and independently associated with adverse outcome. Pirfenidone is an oral anti-fibrotic agent, without haemodynamic effect, that leads to regression of myocardial fibrosis in preclinical models. It has proven clinical effectiveness in pulmonary fibrosis. Methods The PIROUETTE trial is a randomised, double-blind, placebo-controlled phase II trial evaluating the efficacy and safety of 52 weeks of treatment with pirfenidone in patients with chronic HFpEF (symptoms and signs of heart failure, left ventricular ejection fraction ≥ 45%, elevated natriuretic peptides [BNP ≥ 100 pg/ml or NT-proBNP ≥ 300 pg/ml; or BNP ≥ 300 pg/ml or NT-proBNP ≥ 900 pg/ml if in atrial fibrillation]) and myocardial fibrosis (extracellular matrix (ECM) volume ≥ 27% measured using cardiovascular magnetic resonance). The primary outcome measure is change in myocardial ECM volume. A sub-study will investigate the relationship between myocardial fibrosis and myocardial energetics, and the impact of pirfenidone, using 31phosphorus magnetic resonance spectroscopy. Discussion PIROUETTE will determine whether pirfenidone is superior to placebo in relation to regression of myocardial fibrosis and improvement in myocardial energetics in patients with HFpEF and myocardial fibrosis (NCT02932566). Clinical Trial Registration clinicaltrials.gov (NCT02932566) https://clinicaltrials.gov/ct2/show/NCT02932566
2 April 2014 in Journal of Cardiovascular Electrophysiology
13 July 2022 in Journal of the American Heart Association
Background: Growth differentiation factor 15 (GDF‐15) is elevated in heart failure with preserved ejection fraction and is associated with adverse outcome, but its relationship with myocardial fibrosis and other characteristics remains unclear. We sought to evaluate the effect of pirfenidone, a novel antifibrotic agent, on GDF‐15 in heart failure with preserved ejection fraction and identify characteristics that associate with GDF‐15 and with change in GDF‐15 over 1 year. Methods and Results: Among patients enrolled (n=107) in the PIROUETTE (Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction) trial, GDF‐15 was measured at baseline and at prespecified time points in patients randomized (n=94) to pirfenidone or placebo. The response of GDF‐15 to pirfenidone and the association with baseline patient characteristics were evaluated. Pirfenidone had no impact on circulating GDF‐15 at any time point during the 52‐week trial period. In multivariable analysis, male sex, diabetes, higher circulating levels of N‐terminal pro‐B‐type natriuretic peptide, lower renal function, and shorter 6‐minute walk test distance at baseline were associated with baseline log–GDF‐15. Impaired global longitudinal strain at baseline was the strongest predictor of increased GDF‐15 over 52 weeks. Conclusions: In patients with heart failure with preserved ejection fraction, circulating levels of GDF‐15 were unaffected by treatment with pirfenidone and do not appear to be determined by myocardial fibrosis. Circulating GDF‐15 was associated with a spectrum of important heart failure characteristics and it may represent a marker of overall physiological disruption. Registration: URL: https://clinicaltrials.gov/ct2/show/NCT02932566 ; Unique identifier: NCT02932566.
1 April 2011 in The American Journal of Surgery